Thijs J W van de Laar
Overview
Explore the profile of Thijs J W van de Laar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quee F, Slot E, van Leeuwen I, Brands R, Franssen E, Hogema B, et al.
Transfusion
. 2024 Jul;
64(9):1732-1742.
PMID: 38963400
Background: Less discriminatory donor selection policies for men who have sex with men (MSM) may impact transfusion safety in terms of higher residual risks for known transfusion-transmitted infections (TTIs), increased...
2.
Koets L, van Leeuwen K, Derlagen M, van Wijk J, Keijzer N, Feenstra J, et al.
Microbiol Spectr
. 2023 May;
11(3):e0345022.
PMID: 37154727
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOC) pose an increased risk to public health due to higher transmissibility and/or immune escape. In this study, we assessed the...
3.
Slurink I, van de Baan F, van Sighem A, van Dam A, van de Laar T, de Bree G, et al.
Front Reprod Health
. 2022 Oct;
3:568611.
PMID: 36304001
Surveillance of recent HIV infections (RHI) using an avidity assay has been implemented at Dutch sexual health centres (SHC) since 2014, but data on RHI diagnosed at other test locations...
4.
Isfordink C, van de Laar T, Rebers S, Wessels E, Molenkamp R, Knoester M, et al.
Open Forum Infect Dis
. 2021 Aug;
8(8):ofab197.
PMID: 34377722
[This corrects the article DOI: 10.1093/ofid/ofab006.].
5.
Sonneveld M, Veldhuijzen I, van de Laar T, Op de Coul E, van der Meer A
J Hepatol
. 2021 Apr;
77(3):896-897.
PMID: 33887356
No abstract available.
6.
Germain M, Gregoire Y, Custer B, Goldman M, Bravo M, Kamel H, et al.
Vox Sang
. 2021 Apr;
116(10):1084-1093.
PMID: 33835513
Background And Objectives: Efficiency in mitigating HIV transmission risk by transfusion may vary internationally. We compared HIV prevalence and incidence in blood donors across different jurisdictions in relation to those...
7.
Isfordink C, van de Laar T, Rebers S, Wessels E, Molenkamp R, Knoester M, et al.
Open Forum Infect Dis
. 2021 Feb;
8(2):ofab006.
PMID: 33614815
Background: The majority of hepatitis C virus (HCV) infections are found in low- and middle-income countries, which harbor many region-specific HCV subtypes. Nevertheless, direct-acting antiviral (DAA) trials have almost exclusively...
8.
Brandsma E, Verhagen H, van de Laar T, Claas E, Cornelissen M, van den Akker E
J Infect Dis
. 2021 Feb;
223(2):206-213.
PMID: 33535237
Background: Recent advances in CRISPR-based diagnostics suggest that DETECTR, a combination of reverse-transcriptase loop-mediated isothermal amplification (RT-LAMP) and subsequent Cas12 bystander nuclease activation by amplicon-targeting ribonucleoprotein complexes, could be a...
9.
Smit C, Boyd A, Rijnders B, van de Laar T, Leyten E, Bierman W, et al.
Lancet HIV
. 2020 Dec;
8(2):e96-e105.
PMID: 33357835
Background: In the Netherlands, access to direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has been unrestricted for chronic infection since 2015. We evaluated whether the nationwide incidence of HCV...
10.
Newsum A, Matser A, Schinkel J, Van Der Valk M, Brinkman K, van Eeden A, et al.
Clin Infect Dis
. 2020 May;
73(3):460-467.
PMID: 32459339
Background: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at high risk of hepatitis C virus (HCV) reinfection following clearance of HCV, but risk factors specifically...